

GLOBAL AML EDUCATIONAL SCIENTIFIC FORUM

With scientific
endorsement



Daiichi-Sankyo
cancerenterprise

- 08:30 Welcome by Chairs *P Montesinos & M Levis*
-
- 08:35 AML Molecular Biology and Diagnostics
- Clonal evolution - *L Bullinger*
 - Current standards - *J Sierra*
 - Discussion Session - *P Vyas (Session Chair)*
-
- 09:20 New Therapeutics and Combinations in AML – Changing Landscape
- Part A: Focus will be on new drugs, treatment regimens and targeted agents
- Treatment strategies for patients eligible for intensive chemotherapy in newly diagnosed AML - *H Dombret*
 - Treatment strategies for patients not eligible for intensive chemotherapy (unfit) in AML - *A Wei*
- Part B: Focus will be on new drugs, treatment regimens and targeted agents in R/R AML and emerging new targets/approaches - *N Daver*
- Emerging new targets/approaches for AML
 - Discussion - *R Stone (Session Chair)*
-
- 10:25 Break
-
- 10:40 Measurement of MRD in the Treatment of AML:
- Flow cytometry - *J Cloos*
 - Molecular - *C Thiede*
 - Discussion - *T Haferlach (Session Chair)*
-
- 11:30 Future Treatment Strategies in Transplant and Maintenance
- Role of transplant in RR vs. CR1 setting in high-risk AML - *J Uhm*
 - Value of maintenance and promising maintenance regimens in AML - *C Craddock*
 - Discussion - *M Mohty (Session Chair)*
-
- 12:10 Lunch
-
- 13:10 Break-out Workshop Sessions
-
- 14:40 Break
-
- 15:10 Highlights from Break-outs - *Facilitated by P Montesinos & M Levis*
-
- 16:00 Wrap-up presentation and closing remarks - *P Montesinos & M Levis*
-
- 16:30 Meeting adjourned

30 March 2019 | Hilton Barcelona

Chairs

Dr. Pau Montesinos

Hospital Universitari i Politécnic La Fe,
Valencia

Dr. Mark Levis

Johns Hopkins Medicine, Baltimore



Workshop Sessions

Workshops will be 45 minutes each

Delegates attending workshop 1 will switch to workshop 2 at 45 min mark (and vice versa); same for workshops 3 & 4

Session	Topics	Session Leaders
1	FLT3/IDH/WT Case Studies & Discussion – Presentation and discussion of 3 individual cases; 15 min each	<i>R Stone (FLT3)</i> <i>C DiNardo (IDH)</i> <i>D Pollyea (WT)</i>
2	Role of Transplant – Presentation and discussion of a short case study – Will the role of transplant change with the advent of new/emerging therapies? – Will we need transplant when we get these newer agents?	<i>A Venditti</i> <i>M Mohty</i>
3	Testing Practicalities – how does this happen in your region/community? – Diagnostic approach seen – Academic centers vs. community – Time to testing? – Newly diagnosed vs. R/R (both topics are relevant)	<i>T Haferlach</i>
4	New Endpoints in AML and Maintenance Strategies – Clinical trial designs in this era of AML – Strategies around maintenance therapy in AML	<i>P Vyas</i> <i>N Daver</i>

